Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

西力欣 - NMPA Drug Approval Details

Approvals/NMPA/Cefuroxime Sodium for Injection

Approved

化学药品

Cefuroxime Sodium for Injection

GlaxoSmithKline AG🇨🇳 National Medical Products Administration

Approval Date: Nov 4, 2022
Approval ID: ea6fd7bb9f94ccbc
Company: GlaxoSmithKline AG
Type: 化学药品

Approval Details

Approval Id: ea6fd7bb9f94ccbc
Approval Number: 国药准字HJ20181034
Generic Name: 注射用头孢呋辛钠
Generic Name En: Cefuroxime Sodium for Injection
Trade Name: 西力欣
Drug Type: 化学药品
Dosage Form: 注射剂
Strength: 0.75g（按C₁₆H₁₆N₄O₈S计）
Reg Date: 2022-11-04
Expired Date: 2027-11-03
Company Name: GlaxoSmithKline AG
Production Company Name: Acs Dobfar Spa
Company Detail Path: /organization/glaxosmithkline-ag
Production Company Detail Path: /organization/acs-dobfar-spa

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Nov 4, 2022

Approval ID

ea6fd7bb9f94ccbc

Type

化学药品

Back to NMPA Approvals